The UK and US have concluded a important bilateral deal that will ensure no duties on UK medicine exports being sold in the American market.
The Terms of the Deal
As part of the deal, the UK has pledged to raise funding on drugs through the public health system. This move ensures that duties on these crucial exports will stay at zero for a timeframe of 36 months.
This development is in response to earlier threats to hike import taxes on branded drug products, with potential rates discussed as high as double the cost.
"This deal between the UK reinforces the global environment for innovative medicines and establishes much-needed balance to U.S.–U.K. drug exports," a statement said.
Economic Significance
Medicines constitute one of the the United Kingdom's biggest exports to the America, which is clearly the biggest destination for large companies like GSK and AstraZeneca.
Statistics reveal that in the year to the end of the third quarter, the UK sold drugs totaling over eleven billion pounds to the US. This value accounted for a significant portion of all goods exports in that span.
"This deal protects work, boosts funding and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Detailed UK Commitments
The agreement entails several key changes from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise overall public funding on medicines from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. Last year, repayments topped twenty percent.
Industry Background
The deal comes amid a long-running tension between the sector and the UK government over spending levels and NHS adoption.
This friction were intensified by arguments that US customers were paying significantly more for the same drugs than consumers in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while major investments have been pledged toward American operations.
One official publicly accepted that the NHS must increase expenditure on treatments, noting that its spending on drugs had decreased as a share of its resources over the past decade.
